Jeffrey A. Meckler net worth and biography

Jeffrey Meckler Biography and Net Worth

Director of Travere Therapeutics

Jeffrey A. Meckler has served as a director of the Travere Therapeutics since October 2014. Since August 2021, Mr. Meckler has served as chief executive officer of Indaptus Therapeutics, Inc. (formerly Intec Inc.), a biopharmaceutical company. From April 2017 to August 2021, Mr. Meckler served as chief executive officer and vice chair of the board of Intec Pharma, Ltd. He served as chief executive officer and a director of Cocrystal Pharma, Inc., a pharmaceutical company, from April 2015 to July 2016, as a director of QLT, Inc., an ultra-orphan ophthalmic biotechnology company based in Canada, from June 2012 to November 2016, as well as the managing director of The Andra Group, a life sciences consulting firm. Previously, Mr. Meckler acted as a director of several biopharmaceutical companies and medical device companies. Earlier in his career, Mr. Meckler held a series of positions at Pfizer Inc. in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. Mr. Meckler is the past president and continues to serve on the board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in industrial management and M.S. in industrial administration from Carnegie Mellon University. In addition, Mr. Meckler received a J.D. from Fordham University School of Law.

What is Jeffrey A. Meckler's net worth?: The estimated net worth of Jeffrey A. Meckler is at least $1.60 million as of September 30th, 2024. Meckler owns 81,000 shares of Travere Therapeutics stock worth more than $1,598,130 as of March 15th. This net worth estimate does not reflect any other assets that Meckler may own. Learn More about Jeffrey A. Meckler's net worth.
How do I contact Jeffrey A. Meckler?: The corporate mailing address for Meckler and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at ir@retrophin.com. Learn More on Jeffrey A. Meckler's contact information.
Has Jeffrey A. Meckler been buying or selling shares of Travere Therapeutics?: Jeffrey A. Meckler has not been actively trading shares of Travere Therapeutics during the last quarter. Most recently, Jeffrey A. Meckler sold 40,000 shares of the business's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $14.06, for a transaction totalling $562,400.00. Following the completion of the sale, the director now directly owns 81,000 shares of the company's stock, valued at $1,138,860. Learn More on Jeffrey A. Meckler's trading history.
Who are Travere Therapeutics' active insiders?: Travere Therapeutics' insider roster includes Steve Aselage (Director), Roy Baynes (Director), Sandra Calvin (CAO), Laura Clague (CFO), Christopher Cline (Chief Financial Officer), Eric Dube (CEO), Peter Heerma (Insider), Jula Inrig (Insider), Gary Lyons (Director), Jeffrey Meckler (Director), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?: During the last year, insiders at the sold shares 28 times. They sold a total of 329,186 shares worth more than $6,178,934.13. The most recent insider tranaction occured on February, 12th when SVP William E Rote sold 5,200 shares worth more than $122,356.00. Insiders at Travere Therapeutics own 3.8% of the company. Learn More about insider trades at Travere Therapeutics.
Information on this page was last updated on 2/12/2025.

Jeffrey A. Meckler Insider Trading History at Travere Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/30/2024	Sell	40,000	$14.06	$562,400.00	81,000

Jeffrey A. Meckler Buying and Selling Activity at Travere Therapeutics

Travere Therapeutics Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $19.73

$18.86

$19.87

50 Day Range

MA: $20.33

$17.07

$23.75

2 Week Range

Now: $19.73

$5.12

$25.29

Volume

1,137,210 shs

Average Volume

1,411,373 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75